Management Team and Personnel

Glauco R. Souza, Ph.D.
Glauco R. Souza, Ph.D.Founder / Director
Glauco R. Souza, PhD, Co-Founder, Director, former President and CSO of Nano3D Biosciences, and now Director of Global Business Development and Innovation at Greiner Bio-one (GBO). The inventor or co-inventor of all eleven patents related to magnetic 3D cell culture, Glauco is a major influence in the field of 3D cell culture. After GBO IP acquisition, Dr. Souza took the position at GBO to oversee 3D cell culture operations and marketing globally. He is instrumental in any needed product and technical support to be provided by GBO. He is was a former Adjunct Assistant Professor at University of Texas Health Science Center at Houston. His work in 3D cell culture was selected for the Short List of the 2017 Lush Prize for outstanding research producing an effective non-animal safety test Prior to co-founding Nano3D BioSciences, he was an Odyssey Scholar at The University of Texas M. D. Anderson Cancer Center. Glauco R. Souza has a B.S. in Chemistry, and M.S. and Ph.D. in Physical Chemistry from The George Washington University.
Thomas C. Killian, Ph.D.
Thomas C. Killian, Ph.D.Founder / Director
Thomas C. Killian, Ph.D. received a BA in Physics in 1991 from Harvard University, and then attended Cambridge University on a Marshall Scholarship, where he earned an MPhil in physical chemistry in 1993. He received his PhD in atomic physics at the Massachusetts Institute of Technology in 1999, and then completed a post-doctoral fellowship at the National Institute of Standards and Technology. In 2001, Dr. Killian became an Assistant Professor of Physics and Astronomy at William Marsh Rice University where he conducts research on the properties of matter at temperatures as low as a few billionths of a degree above absolute zero. He served as the Chair of the Department of Physics and Astronomy from 2012-2016 and is currently the Associate Dean for Strategic Planning in the Wiess School of Natural Sciences at Rice. He is also a co-founder and Director of ChemoSen3D, Inc., which is developing assays that use a patient’s own cells to identify the optimal therapeutic treatment for cancer.
Chad Brinkley, BA
Chad Brinkley, BAChairman, President & CEO
Mr. Brinkley is an entrepreneur that has primarily focused on the Aerospace & Defense Market with a concentration in space. He founded several companies in this arena that provide solutions to NASA, Department of Defense, National Reconnaissance Office and commercial space companies. His interest in the biotechnology world began at the Center for The Advancement of Science in Space (CASIS) that manages the International Space Station National Laboratory (ISS-NL). In this role he managed the technology development portfolio as a member of the business development team. Through this experience of flying many different science project to the ISS he became interested in joining the C3D team and licensing drug delivery system technologies from the Houston Methodist Research Institute (HMRI).
Christina van Lier, PhD
Christina van Lier, PhDCSO
Dr. van Lier is experienced in establishment and maintenance of CLIA-certified/CAP-accredited laboratories in the pharmacogenomics, molecular diagnostic, and infectious disease testing spaces. She received her PhD in Microbiology and Immunology at the University of Texas Medical Branch working in high containment at the Galveston National Laboratory.

3D Cell Culture  •  Biotechnology  •  Clinical Diagnostics  •  Nanoparticles